• 1
    Wilde MI & McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid related disorders. Drugs 1994; 48: 91 132.
  • 2
    Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903 12.
  • 3
    Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356 70.
  • 4
    Regårdh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1986; 21(Suppl. 118): 99 104.
  • 5
    Cederberg C, Andersson T, Skånberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989; 24(Suppl. 166): 33 40.
  • 6
    Andersson T, Regårdh CG, Lou YC, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 32 7.
  • 7
    Sohn DR, Kobayashi K, Lee KH, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4-hydroxylation recruited from Oriental population. J Pharmacol Exp Ther 1992; 262: 1195 202.
  • 8
    Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985; 38: 402 8.
  • 9
    Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388 97.
  • 10
    Bertilsson L & Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese population? Clin Pharmacol Ther 1993; 53: 608 10.
  • 11
    De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419 22.
  • 12
    Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358 63.
  • 13
    De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594 8.
  • 14
    Sagar M, Tybring G, Dahl ML, et al. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid related disorders with and without H. pylori infection. Scand J Gastroenterol 1998; 33: 1034 8.
  • 15
    Solcia E, Capella C, Buffa R, et al. The diffuse endocrine–paracrine system of the gut in health and disease: ultrastructural features. Scand J Gastroenterol 1981; 16(Suppl. 70): 25 36.
  • 16
    Håkanson R, Axelson J, Ekman R, et al. Hypergastrinaemia evoked by omeprazole stimulates growth of gastric mucosa but not of pancreas or intestines in hamster, guinea pig and chicken. Regul Pept 1988; 23: 105 15.
  • 17
    Ryberg B, Tielemans Y, Axelson J, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990; 99: 935 42.
  • 18
    Bordi C, Costa A, Missale G. ECL cell proliferation and gastrin level. Gastroenterology 1975; 68: 205 6.
  • 19
    Borch K, Renvall H, Liedberg G, et al. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986; 2: 357 63.
  • 20
    Cattan D, Roucayrol AM, Launay JM, et al. Circulating gastrin, endocrine cells, histamine content, and histidine decarboxylase activity in atrophic gastritis. Gastroenterology 1989; 97: 586 96.
  • 21
    Bordi C, Cocconi G, Togni R, et al. Gastric endocrine cell proliferation. Association with Zollinger–Ellison syndrome. Arch Pathol 1974; 98: 274 9.
  • 22
    Solcia E, Capella C, Fiocca R, et al. Gastric argyrophil carcinoidosis in patients with Zollinger–Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990; 14: 503 13.
  • 23
    Stridsberg M, Hellman U, Wilander E, et al. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993; 139: 329 37.
  • 24
    Stridsberg M, Öberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49 59.
  • 25
    Syversen U, Mignon M, Bonfils S, et al. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncologica 1993; 32: 161 5.
  • 26
    Borch K, Stridsberg M, Burman P, et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32: 198 202.
  • 27
    Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649 53.
  • 28
    Houben P, Lundqvist G, Biemond I, et al. Twenty-four-hour intragastric pH, basal and meal-stimulated serum gastrin, and plasma chromogranin A after short-term acid inhibition. Gastroenterology 1997; 112: A152 A152(Abstract).
  • 29
    Kekki M, Samloff IM, Varis K, et al. Serum pepsinogen I and serum gastrin in the secreening of severe atrophic corpus gastritis. Scand J Gastroenterol 1991; 26(Suppl. 186): 109 16.
  • 30
    Festen HP, Thijs JC, Lamers CB, et al. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology 1984; 87: 1030 4.
  • 31
    Sagar M, Janczewska I, Ljungdahl Å, et al. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther 1999; 13: 453 8.
  • 32
    Lundqvist G & Wide L. Serum gastrin determination with a radioimmunosorbent technique. Clinica Chemica Acta 1977; 79: 357 62.
  • 33
    Befrits R, Granström M, Rylander M, et al. Helicobacter pylori in 205 consecutive endoscopy patients. Scand J Infect Dis 1993; 25: 185 91.
  • 34
    Granström M, Tindberg Y, Blennow M. Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age. J Clin Microbiol 1997; 35: 468 70.
  • 35
    Chang M, Tybring G, Dahl ML, et al. Inter phenotype differences in disposition and effect on gastrin levels of omeprazole. Suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511 8.
  • 36
    Sagar M, Tybring G, Dahl M-L, et al. The effect of omeprazole on intragastric pH and gastrin levels is determined by the CYP2C19 polymorphism more than by H. pylori infection in patients with acid related disease. Gastroenterology 1998; 114: A1122 A1122.
  • 37
    Furuta T, Ohashik K, Takaahima M, et al. CYP2C19 genotype status and effect of omeprazole. Gastroenterology 1998; 114: A0521 A0521.
  • 38
    Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric acid secretion. Digestion 1986; 35(Suppl. 1): 42 55.
  • 39
    Lamberts R, Crutzfeldt W, Stöckmann F, et al. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988; 39: 126 35.
  • 40
    Penston JG, Dixon JS, Selway SAM, et al. Gastric histology and plasma gastrin response to a meal in patients with duodenal ulcer disease after five years treatment with ranitidine. Aliment Pharmacol Ther 1990; 4: 381 92.
  • 41
    Eissele R, Brunner G, Solcia E, et al. Gastric mucosa during treatment with lanzoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707 17.
  • 42
    Berstad AE, Hatlebakk JG, Maartmann-Moe H, et al. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lanzoprazole. Gut 1997; 41: 740 7.
  • 43
    Kuipers EJ, Klinkenberg-Knol EC, Festen HP, et al. Lanzoprazole, H. pylori, and atrophic gastritis . Gastroenterology 1997; 113: 2018 9.
  • 44
    Kuipers EJ, Lundell L, Klinkenberg EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundiplication. N Engl Med 1996; 334: 1018 22.
  • 45
    Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525 8.
  • 46
    Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-time safety . Am J Gastroenterol 1995; 90: 1401 6.
  • 47
    Biemond I, Crobach LFSJ, Jansen JBMJ, et al. Effect of short-term omeprazole administraion on serum pepsinogens in relation to fasting serum gastrin and gastric acid secretion. Eur J Clin Pharmacol 1989; 37: 345 9.
  • 48
    Meijer JL, Jansen JBMJ, Biemond I, et al. Effect of short-term administration of omeprazole on serum gastrin and pepsinogens in antrectomized patients. Digestion 1993; 54: 139 42.
  • 49
    Iwao T, Toyonaga A, Kuboyama S, et al. Effects of omeprazole and lansoprazole on fasting and postprandial serum gastrin and serum pepsinogen A and C. Hepatogastroenterology 1995; 42: 677 82.
  • 50
    Jansen JBMJ, Klinkenberg-Knol EC, Meuwissen SGM, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990; 99: 621 8.